{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T23:53:22Z","timestamp":1784159602896,"version":"3.55.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2021,7,14]],"date-time":"2021-07-14T00:00:00Z","timestamp":1626220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,7,14]],"date-time":"2021-07-14T00:00:00Z","timestamp":1626220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1007\/s10792-021-01947-2","type":"journal-article","created":{"date-parts":[[2021,7,14]],"date-time":"2021-07-14T15:03:50Z","timestamp":1626275030000},"page":"3825-3835","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Comparison of BAK-preserved latanoprost and polyquad-preserved travoprost on ocular surface parameters in patients with glaucoma and ocular hypertension"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2264-9591","authenticated-orcid":false,"given":"Omer Ersin","family":"Muz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenan","family":"Dagdelen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuncay","family":"Pirdal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mete","family":"Guler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,14]]},"reference":[{"issue":"4","key":"1947_CR1","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1111\/j.1442-9071.2012.02773.x","volume":"40","author":"RJ Casson","year":"2012","unstructured":"Casson RJ, Chidlow G, Wood JP, Crowston JG, Goldberg I (2012) Definition of glaucoma: clinical and experimental concepts. Clin Exp Ophthalmol 40(4):341\u2013349","journal-title":"Clin Exp Ophthalmol"},{"issue":"2","key":"1947_CR2","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1097\/IJG.0b013e31802fc6d3","volume":"16","author":"CB Toris","year":"2007","unstructured":"Toris CB, Zhan G, Fan S, Dickerson JE, Landry TA, Bergamini MV, Camras CB (2007) Effects of travoprost on aqueous humor dynamics in patients with elevated intraocular pressure. J Glaucoma 16(2):189\u2013195","journal-title":"J Glaucoma"},{"issue":"3","key":"1947_CR3","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.jtos.2017.05.004","volume":"15","author":"JAP Gomes","year":"2017","unstructured":"Gomes JAP, Azar DT, Baudouin C, Efron N, Hirayama M, Horwath-Winter J, Kim T, Mehta JS, Messmer EM, Pepose JS et al (2017) TFOS DEWS II iatrogenic report. Ocul Surf 15(3):511\u2013538","journal-title":"Ocul Surf"},{"issue":"7","key":"1947_CR4","first-page":"335","volume":"61","author":"A Orozco Garcia","year":"2020","unstructured":"Orozco Garcia A, Giorgi-Sandoval LA, Paczka JA, Garcia y Otero S\u00e1nchez SA, Valencia-Paredes D, Ponce-Horta AM, Rueda D, Vazquez IF (2020) Dry eye disease prevalence exponentially increases with age in patients under topical glaucoma treatment. Invest Ophthalmol Vis Sci 61(7):335\u2013335","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"6","key":"1947_CR5","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1097\/ICO.0b013e3181c325b2","volume":"29","author":"RD Fechtner","year":"2010","unstructured":"Fechtner RD, Godfrey DG, Budenz D, Stewart JA, Stewart WC, Jasek MC (2010) Prevalence of ocular surface complaints in patients with glaucoma using topical intraocular pressure-lowering medications. Cornea 29(6):618\u2013621","journal-title":"Cornea"},{"issue":"5","key":"1947_CR6","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1097\/IJG.0b013e31815c5f4f","volume":"17","author":"EW Leung","year":"2008","unstructured":"Leung EW, Medeiros FA, Weinreb RN (2008) Prevalence of ocular surface disease in glaucoma patients. J Glaucoma 17(5):350\u2013355","journal-title":"J Glaucoma"},{"issue":"11","key":"1947_CR7","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1007\/s00417-008-0881-9","volume":"246","author":"C Erb","year":"2008","unstructured":"Erb C, Gast U, Schremmer D (2008) German register for glaucoma patients with dry eye: I: basic outcome with respect to dry eye. Graefes Arch Clin Exp Ophthalmol 246(11):1593\u20131601","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"3","key":"1947_CR8","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.clae.2015.02.001","volume":"38","author":"A Camp","year":"2015","unstructured":"Camp A, Wellik SR, Tzu JH, Feuer W, Arheart KL, Sastry A, Galor A (2015) Dry eye specific quality of life in veterans using glaucoma drops. Cont Lens Anterior Eye 38(3):220\u2013225","journal-title":"Cont Lens Anterior Eye"},{"issue":"3","key":"1947_CR9","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.jtos.2017.05.003","volume":"15","author":"F Stapleton","year":"2017","unstructured":"Stapleton F, Alves M, Bunya VY, Jalbert I, Lekhanont K, Malet F, Na KS, Schaumberg D, Uchino M, Vehof J et al (2017) TFOS DEWS II epidemiology report. Ocul Surf 15(3):334\u2013365","journal-title":"Ocul Surf"},{"issue":"3","key":"1947_CR10","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.jtos.2017.05.011","volume":"15","author":"AJ Bron","year":"2017","unstructured":"Bron AJ, de Paiva CS, Chauhan SK, Bonini S, Gabison EE, Jain S, Knop E, Markoulli M, Ogawa Y, Perez V et al (2017) TFOS DEWS II pathophysiology report. Ocul Surf 15(3):438\u2013510","journal-title":"Ocul Surf"},{"issue":"4","key":"1947_CR11","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1136\/bjo.86.4.418","volume":"86","author":"PJ Pisella","year":"2002","unstructured":"Pisella PJ, Pouliquen P, Baudouin C (2002) Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br J Ophthalmol 86(4):418\u2013423","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"1947_CR12","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1586\/17469899.4.1.59","volume":"4","author":"MY Kahook","year":"2009","unstructured":"Kahook MY (2009) Preservatives in topical ophthalmic medications: historical and clinical perspectives AU\u2014Freeman, P David. Exp Rev Ophthalmol 4(1):59\u201364","journal-title":"Exp Rev Ophthalmol"},{"key":"1947_CR13","first-page":"2131","volume":"7","author":"LM Rosin","year":"2013","unstructured":"Rosin LM, Bell NP (2013) Preservative toxicity in glaucoma medication: clinical evaluation of benzalkonium chloride-free 0.5% timolol eye drops. Clin Ophthalmol 7:2131\u20132135","journal-title":"Clin Ophthalmol"},{"issue":"7","key":"1947_CR14","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1111\/j.1755-3768.2008.01250.x","volume":"86","author":"C Baudouin","year":"2008","unstructured":"Baudouin C (2008) Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma. Acta Ophthalmol 86(7):716\u2013726","journal-title":"Acta Ophthalmol"},{"issue":"4","key":"1947_CR15","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.preteyeres.2010.03.001","volume":"29","author":"C Baudouin","year":"2010","unstructured":"Baudouin C, Labb\u00e9 A, Liang H, Pauly A, Brignole-Baudouin F (2010) Preservatives in eyedrops: the good, the bad and the ugly. Prog Retin Eye Res 29(4):312\u2013334","journal-title":"Prog Retin Eye Res"},{"issue":"4","key":"1947_CR16","doi-asserted-by":"publisher","first-page":"270","DOI":"10.3341\/kjo.2015.29.4.270","volume":"29","author":"JH Kim","year":"2015","unstructured":"Kim JH, Kim EJ, Kim YH, Kim YI, Lee SH, Jung JC, Lee KW, Park YJ (2015) In vivo effects of preservative-free and preserved prostaglandin analogs: mouse ocular surface study. Korean J Ophthalmol 29(4):270\u2013279","journal-title":"Korean J Ophthalmol"},{"issue":"11","key":"1947_CR17","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1136\/bjophthalmol-2017-311544","volume":"102","author":"DW Steven","year":"2018","unstructured":"Steven DW, Alaghband P, Lim KS (2018) Preservatives in glaucoma medication. Br J Ophthalmol 102(11):1497\u20131503","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"1947_CR18","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1177\/112067210701700311","volume":"17","author":"N Jaenen","year":"2007","unstructured":"Jaenen N, Baudouin C, Pouliquen P, Manni G, Figueiredo A, Zeyen T (2007) Ocular symptoms and signs with preserved and preservative-free glaucoma medications. Eur J Ophthalmol 17(3):341\u2013349","journal-title":"Eur J Ophthalmol"},{"key":"1947_CR19","doi-asserted-by":"publisher","first-page":"103","DOI":"10.2147\/OPTH.S28104","volume":"6","author":"I Janulevi\u010dien\u0117","year":"2012","unstructured":"Janulevi\u010dien\u0117 I, Derka\u010d I, Grybauskiene L, Paulauskait\u0117 R, Gromnickaite R, Kuzmien\u0117 L (2012) Effects of preservative-free taflup rost on tear film osmolarity, tolerability, and intraocular pressure in previously treated patients with open-angle glaucoma. Clin Ophthalmol 6:103\u2013109","journal-title":"Clin Ophthalmol"},{"issue":"3","key":"1947_CR20","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1111\/j.1755-3768.2010.01907.x","volume":"88","author":"H Uusitalo","year":"2010","unstructured":"Uusitalo H, Chen E, Pfeiffer N, Brignole-Baudouin F, Kaarniranta K, Leino M, Puska P, Palmgren E, Hamacher T, Hofmann G et al (2010) Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication. Acta Ophthalmol 88(3):329\u2013336","journal-title":"Acta Ophthalmol"},{"issue":"5","key":"1947_CR21","doi-asserted-by":"publisher","first-page":"391","DOI":"10.3109\/02713683.2011.562340","volume":"36","author":"WC Stewart","year":"2011","unstructured":"Stewart WC, Stewart JA, Nelson LA (2011) Ocular surface disease in patients with ocular hypertension and glaucoma. Curr Eye Res 36(5):391\u2013398","journal-title":"Curr Eye Res"},{"issue":"5","key":"1947_CR22","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1001\/archopht.118.5.615","volume":"118","author":"RM Schiffman","year":"2000","unstructured":"Schiffman RM, Christianson MD, Jacobsen G, Hirsch JD, Reis BL (2000) Reliability and validity of the ocular surface disease index. Arch Ophthalmol 118(5):615\u2013621","journal-title":"Arch Ophthalmol"},{"issue":"3","key":"1947_CR23","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.ajo.2009.09.013","volume":"149","author":"JP Whitcher","year":"2010","unstructured":"Whitcher JP, Shiboski CH, Shiboski SC, Heidenreich AM, Kitagawa K, Zhang S, Hamann S, Larkin G, McNamara NA, Greenspan JS et al (2010) A simplified quantitative method for assessing keratoconjunctivitis sicca from the Sj\u00f6gren\u2019s Syndrome International Registry. Am J Ophthalmol 149(3):405\u2013415","journal-title":"Am J Ophthalmol"},{"key":"1947_CR24","first-page":"785","volume":"9","author":"HG Lemij","year":"2015","unstructured":"Lemij HG, Hoevenaars JG, van der Windt C, Baudouin C (2015) Patient satisfaction with glaucoma therapy: Reality or myth? Clin Ophthalmol 9:785\u2013793","journal-title":"Clin Ophthalmol"},{"key":"1947_CR25","first-page":"441","volume":"6","author":"J Garcia-Feijoo","year":"2012","unstructured":"Garcia-Feijoo J, Sampaolesi JR (2012) A multicenter evaluation of ocular surface disease prevalence in patients with glaucoma. Clin Ophthalmol 6:441\u2013446","journal-title":"Clin Ophthalmol"},{"issue":"2","key":"1947_CR26","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1097\/ICU.0b013e328089f1c8","volume":"18","author":"RW Yee","year":"2007","unstructured":"Yee RW (2007) The effect of drop vehicle on the efficacy and side effects of topical glaucoma therapy: a review. Curr Opin Ophthalmol 18(2):134\u2013139","journal-title":"Curr Opin Ophthalmol"},{"issue":"3","key":"1947_CR27","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/S0161-6420(99)90116-1","volume":"106","author":"C Baudouin","year":"1999","unstructured":"Baudouin C, Pisella PJ, Fillacier K, Goldschild M, Becquet F, De Saint JM, B\u00e9chetoille A (1999) Ocular surface inflammatory changes induced by topical antiglaucoma drugs: human and animal studies. Ophthalmology 106(3):556\u2013563","journal-title":"Ophthalmology"},{"issue":"1","key":"1947_CR28","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/IJG.0b013e3181d26024","volume":"20","author":"H Kobayashi","year":"2011","unstructured":"Kobayashi H, Kobayashi K (2011) A correlation between latanoprost-induced conjunctival hyperemia and intraocular pressure-lowering effect. J Glaucoma 20(1):3\u20136","journal-title":"J Glaucoma"},{"issue":"1","key":"1947_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ajo.2011.05.033","volume":"153","author":"SE Skalicky","year":"2012","unstructured":"Skalicky SE, Goldberg I, McCluskey P (2012) Ocular surface disease and quality of life in patients with glaucoma. Am J Ophthalmol 153(1):1-9.e2","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"1947_CR30","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.ophtha.2005.10.034","volume":"113","author":"B Sleath","year":"2006","unstructured":"Sleath B, Robin AL, Covert D, Byrd JE, Tudor G, Svarstad B (2006) Patient-reported behavior and problems in using glaucoma medications. Ophthalmology 113(3):431\u2013436","journal-title":"Ophthalmology"},{"issue":"1","key":"1947_CR31","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1097\/IJG.0b013e318264cd68","volume":"23","author":"R Batra","year":"2014","unstructured":"Batra R, Tailor R, Mohamed S (2014) Ocular surface disease exacerbated glaucoma: optimizing the ocular surface improves intraocular pressure control. J Glaucoma 23(1):56\u201360","journal-title":"J Glaucoma"},{"key":"1947_CR32","doi-asserted-by":"publisher","first-page":"103","DOI":"10.2147\/OPTH.S229815","volume":"14","author":"AL Mylla Boso","year":"2020","unstructured":"Mylla Boso AL, Gasperi E, Fernandes L, Costa VP, Alves M (2020) Impact of ocular surface disease treatment in patients with glaucoma. Clin Ophthalmol 14:103\u2013111","journal-title":"Clin Ophthalmol"},{"issue":"6","key":"1947_CR33","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1167\/iovs.17-21795","volume":"58","author":"R Mastropasqua","year":"2017","unstructured":"Mastropasqua R, Fasanella V, Brescia L, Oddone F, Mariotti C, Di Staso S, Agnifili L (2017) In vivo confocal imaging of the conjunctiva as a predictive tool for the glaucoma filtration surgery outcome. Invest Ophthalmol Vis Sci 58(6):114\u2013120","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"1947_CR34","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1097\/IJG.0b013e3181fc8129","volume":"21","author":"M Aihara","year":"2012","unstructured":"Aihara M, Otani S, Kozaki J, Unoki K, Takeuchi M, Minami K, Miyata K (2012) Long-term effect of BAK-free travoprost on ocular surface and intraocular pressure in glaucoma patients after transition from latanoprost. J Glaucoma 21(1):60\u201364","journal-title":"J Glaucoma"},{"issue":"5","key":"1947_CR35","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1097\/01.ico.0000116526.57227.82","volume":"23","author":"RJ Noecker","year":"2004","unstructured":"Noecker RJ, Herrygers LA, Anwaruddin R (2004) Corneal and conjunctival changes caused by commonly used glaucoma medications. Cornea 23(5):490\u2013496","journal-title":"Cornea"},{"key":"1947_CR36","first-page":"291","volume":"3","author":"MB Horsley","year":"2009","unstructured":"Horsley MB, Kahook MY (2009) Effects of prostaglandin analog therapy on the ocular surface of glaucoma patients. Clin Ophthalmol 3:291\u2013295","journal-title":"Clin Ophthalmol"},{"issue":"6","key":"1947_CR37","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/BF02849799","volume":"20","author":"T Mundorf","year":"2003","unstructured":"Mundorf T, Wilcox KA, Ousler GW 3rd, Welch D, Abelson MB (2003) Evaluation of the comfort of Alphagan P compared with Alphagan in irritated eyes. Adv Ther 20(6):329\u2013336","journal-title":"Adv Ther"},{"issue":"11","key":"1947_CR38","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1007\/s12325-010-0070-1","volume":"27","author":"DA Ammar","year":"2010","unstructured":"Ammar DA, Noecker RJ, Kahook MY (2010) Effects of benzalkonium chloride-preserved, polyquad-preserved, and sofZia-preserved topical glaucoma medications on human ocular epithelial cells. Adv Ther 27(11):837\u2013845","journal-title":"Adv Ther"},{"key":"1947_CR39","first-page":"1189","volume":"18","author":"T Paimela","year":"2012","unstructured":"Paimela T, Ryh\u00e4nen T, Kauppinen A, Marttila L, Salminen A, Kaarniranta K (2012) The preservative polyquaternium-1 increases cytoxicity and NF-kappaB linked inflammation in human corneal epithelial cells. Mol Vis 18:1189\u20131196","journal-title":"Mol Vis"},{"key":"1947_CR40","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.2147\/OPTH.S211611","volume":"13","author":"K Walsh","year":"2019","unstructured":"Walsh K, Jones L (2019) The use of preservatives in dry eye drops. Clin Ophthalmol 13:1409\u20131425","journal-title":"Clin Ophthalmol"},{"issue":"4","key":"1947_CR41","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.clae.2005.08.002","volume":"28","author":"CE Codling","year":"2005","unstructured":"Codling CE, Hann AC, Maillard JY, Russell AD (2005) An investigation into the antimicrobial mechanisms of action of two contact lens biocides using electron microscopy. Cont Lens Anterior Eye 28(4):163\u2013168","journal-title":"Cont Lens Anterior Eye"},{"issue":"11","key":"1947_CR42","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1517\/17425247.2011.617736","volume":"8","author":"M Rolando","year":"2011","unstructured":"Rolando M, Crider JY, Kahook MY (2011) Ophthalmic preservatives: focus on polyquaternium-1. Expert Opin Drug Deliv 8(11):1425\u20131438","journal-title":"Expert Opin Drug Deliv"},{"issue":"11","key":"1947_CR43","doi-asserted-by":"publisher","first-page":"979","DOI":"10.3109\/02713683.2011.578781","volume":"36","author":"F Brignole-Baudouin","year":"2011","unstructured":"Brignole-Baudouin F, Riancho L, Liang H, Baudouin C (2011) Comparative in vitro toxicology study of travoprost polyquad-preserved, travoprost BAK-preserved, and latanoprost BAK-preserved ophthalmic solutions on human conjunctival epithelial cells. Curr Eye Res 36(11):979\u2013988","journal-title":"Curr Eye Res"},{"issue":"3","key":"1947_CR44","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1089\/jop.2010.0111","volume":"27","author":"F Brignole-Baudouin","year":"2011","unstructured":"Brignole-Baudouin F, Riancho L, Liang H, Nakib Z, Baudouin C (2011) In vitro comparative toxicology of polyquad-preserved and benzalkonium chloride-preserved travoprost\/timolol fixed combination and latanoprost\/timolol fixed combination. J Ocul Pharmacol Ther 27(3):273\u2013280","journal-title":"J Ocul Pharmacol Ther"},{"issue":"4","key":"1947_CR45","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1089\/jop.2006.22.267","volume":"22","author":"A Labb\u00e9","year":"2006","unstructured":"Labb\u00e9 A, Pauly A, Liang H, Brignole-Baudouin F, Martin C, Warnet JM, Baudouin C (2006) Comparison of toxicological profiles of benzalkonium chloride and polyquaternium-1: an experimental study. J Ocul Pharmacol Ther 22(4):267\u2013278","journal-title":"J Ocul Pharmacol Ther"},{"issue":"3","key":"1947_CR46","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3109\/15569527.2014.944650","volume":"34","author":"HJ Lee","year":"2015","unstructured":"Lee HJ, Jun RM, Cho MS, Choi KR (2015) Comparison of the ocular surface changes following the use of two different prostaglandin F2\u03b1 analogues containing benzalkonium chloride or polyquad in rabbit eyes. Cutan Ocul Toxicol 34(3):195\u2013202","journal-title":"Cutan Ocul Toxicol"},{"issue":"4","key":"1947_CR47","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s12325-011-0003-7","volume":"28","author":"H Liang","year":"2011","unstructured":"Liang H, Brignole-Baudouin F, Pauly A, Riancho L, Baudouin C (2011) Polyquad-preserved travoprost\/timolol, benzalkonium chloride (BAK)-preserved travoprost\/timolol, and latanoprost\/timolol in fixed combinations: a rabbit ocular surface study. Adv Ther 28(4):311\u2013325","journal-title":"Adv Ther"},{"issue":"5","key":"1947_CR48","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1517\/14740338.2015.1017467","volume":"14","author":"GC Rossi","year":"2015","unstructured":"Rossi GC, Scudeller L, Rolle T, Pasinetti GM, Bianchi PE (2015) From benzalkonium chloride-preserved Latanoprost to Polyquad-preserved Travoprost: a 6-month study on ocular surface safety and tolerability. Expert Opin Drug Saf 14(5):619\u2013623","journal-title":"Expert Opin Drug Saf"},{"key":"1947_CR49","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/s12886-015-0151-7","volume":"15","author":"JF Lopes","year":"2015","unstructured":"Lopes JF, Hubatsch DA, Amaris P (2015) Effect of benzalkonium chloride-free travoprost on intraocular pressure and ocular surface symptoms in patients with glaucoma previously on latanoprost: an open-label study. BMC Ophthalmol 15:166","journal-title":"BMC Ophthalmol"},{"issue":"3","key":"1947_CR50","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s12253-014-9755-0","volume":"20","author":"L Marsovszky","year":"2014","unstructured":"Marsovszky L, Resch MD, Visontai Z, N\u00e9meth J (2014) Confocal microscopy of epithelial and langerhans cells of the cornea in patients using travoprost drops containing two different preservatives. Pathol Oncol Res 20(3):741\u2013746","journal-title":"Pathol Oncol Res"},{"issue":"2","key":"1947_CR51","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1111\/j.1444-0938.2011.00687.x","volume":"95","author":"CK Choy","year":"2012","unstructured":"Choy CK, Cho P, Boost MV (2012) Cytotoxicity and effects on metabolism of contact lens care solutions on human corneal epithelium cells. Clin Exp Optom 95(2):198\u2013206","journal-title":"Clin Exp Optom"},{"key":"1947_CR52","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.2147\/OPTH.S13460","volume":"4","author":"MJ Miyashiro","year":"2010","unstructured":"Miyashiro MJ, Lo SC, Stewart JA, Stewart WC (2010) Efficacy, safety, and tolerability of travoprost 0.004% BAK-free versus prior treatment with latanoprost 0.005% in Japanese patients. Clin Ophthalmol 4:1355\u20131359","journal-title":"Clin Ophthalmol"},{"issue":"3","key":"1947_CR53","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1111\/ceo.12431","volume":"43","author":"I Goldberg","year":"2015","unstructured":"Goldberg I, Graham SL, Crowston JG, d\u2019Mellow G (2015) Clinical audit examining the impact of benzalkonium chloride-free anti-glaucoma medications on patients with symptoms of ocular surface disease. Clin Exp Ophthalmol 43(3):214\u2013220","journal-title":"Clin Exp Ophthalmol"},{"key":"1947_CR54","doi-asserted-by":"publisher","first-page":"1319628","DOI":"10.1155\/2018\/1319628","volume":"2018","author":"WG El Hajj Moussa","year":"2018","unstructured":"El Hajj Moussa WG, Farhat RG, Nehme JC, Sahyoun MA, Schakal AR, Jalkh AE, Abi Karam MP, Azar GG (2018) Comparison of efficacy and ocular surface disease index score between bimatoprost, latanoprost, travoprost, and tafluprost in glaucoma patients. J Ophthalmol 2018:1319628","journal-title":"J Ophthalmol"},{"issue":"3","key":"1947_CR55","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.jtos.2017.04.001","volume":"15","author":"DA Sullivan","year":"2017","unstructured":"Sullivan DA, Rocha EM, Aragona P, Clayton JA, Ding J, Golebiowski B, Hampel U, McDermott AM, Schaumberg DA, Srinivasan S et al (2017) TFOS DEWS II sex, gender, and hormones report. Ocul Surf 15(3):284\u2013333","journal-title":"Ocul Surf"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-021-01947-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10792-021-01947-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-021-01947-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,25]],"date-time":"2021-10-25T20:34:41Z","timestamp":1635194081000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10792-021-01947-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,14]]},"references-count":55,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["1947"],"URL":"https:\/\/doi.org\/10.1007\/s10792-021-01947-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-230328\/v1","asserted-by":"object"}]},"ISSN":["0165-5701","1573-2630"],"issn-type":[{"value":"0165-5701","type":"print"},{"value":"1573-2630","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,14]]},"assertion":[{"value":"10 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Patients signed informed consent regarding publishing their data.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Approval was obtained from the ethics committee of Firat University of Medical Sciences (Date:09\/20\/2018 No:15\/01). All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}